Board approves sale of identified diagnostic equipment for up to ₹120 crore

The Board has approved the sale of identified diagnostic equipment for an aggregate consideration of up to ₹120 crore to identified purchaser(s), including those identified in future.

Mon 28 Sep 2026

Equipment Sale Approval

up to ₹120 crore

Strategic Model

asset-light, capital-efficient model

Asset Type

freehold assets not subject to lender security

Expected Impact

no material adverse impact on P&L or operations

What was approved

The Board of Directors approved the sale of identified diagnostic equipment for an aggregate consideration of up to ₹120 crore to identified purchaser(s), including purchaser(s) that may be identified in the future.

Stated rationale

• Part of an ongoing strategic initiative to optimise the asset portfolio and enhance capital efficiency.
• The company says it is moving towards an increasingly asset-light and capital-efficient operating model, and has identified assets that can be monetised without impacting core operating capabilities.
• Proceeds are intended for efficient recycling of capital into the core diagnostic business and identified growth opportunities.
• Expected to support improved asset utilisation, enhance return on capital employed (ROCE) and strengthen the balance sheet.

On lenders and security

The assets proposed to be sold are identified freehold assets that are not subject to any security interest created in favour of the company's lenders. Accordingly, the company states the transaction will not impact the assets forming part of the security package provided to lenders.

Impact flagged by the company

• The transaction is described as portfolio and capital optimisation, and not driven by any impairment or diminution in the value of the underlying assets.
• It is not expected to have any material adverse impact on the profit and loss account or ongoing business operations.
• It does not constitute a sale, lease or disposal of an undertaking or substantially the whole of the undertaking under Section 180(1)(a) of the Companies Act, 2013.

Execution

The Board authorised the Operations Committee to finalise the terms and conditions and complete necessary formalities, within the approved aggregate limit.

How investors may read it

The size is capped at up to ₹120 crore, and it is an approval — buyers and final terms are still to be settled. Investors may watch for subsequent disclosures on actual sales concluded, the gain or loss recorded, and how the freed-up capital is deployed.

Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.